logo-loader

VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Published: 08:17 09 May 2019 EDT

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash.

''Total cash in hand that gives us around $21.2mln ... so it's a really good runway to get our milestones completed''.

Reynolds also updates on operational developments including their first large-scale lung cancer study being carried out in Taiwan.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

54 minutes ago